NCT05714124 Liver Embolization Approaches for Tumor Management
| NCT ID | NCT05714124 |
| Status | Recruiting |
| Phase | — |
| Sponsor | IRCCS San Raffaele |
| Condition | Hepatocellular Carcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 580 participants |
| Start Date | 2021-05-21 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 580 participants in total. It began in 2021-05-21 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this evaluate short, medium and long term outcome of the different embolization techniques in patients with primary and secondary hepatic tumors. The main aim is to evaluate progression free survival following embolization in this study population or evaluate residual hepatic volume in cases in which these techniques are used to induce liver regeneration. This study is an observational registry - all patients will follow their normal therapeutic and treatment scheme as per clinical practice, without any additional intervention.
Eligibility Criteria
Inclusion Criteria: * ≥ 18 yoa * patients with patients with primary or secondary liver disease not amenable for surgery or ablation * patients with primary or secondary liver tumors candidates for major surgery prior to induction of hypertrophy * able and willing to sign informed consent Exclusion Criteria: * pregnant women * patients with uncorrectable coagulopathy * diffuse extrahepatic disease * for lobar TACE and TARE - presence of bilodigestive shunt * for TARE - \>20% hepatopulmonary shunt
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05714124 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hepatocellular Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05714124 currently recruiting?
Yes, NCT05714124 is actively recruiting participants. Contact the research team at trialcliniciradiologia@hsr.it for enrollment information.
Where is the NCT05714124 trial being conducted?
This trial is being conducted at Milan, Italy.
Who is sponsoring the NCT05714124 clinical trial?
NCT05714124 is sponsored by IRCCS San Raffaele. The trial plans to enroll 580 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.